168 related articles for article (PubMed ID: 37568909)
1. Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas.
Soukup J; Gerykova L; Rachelkar A; Hornychova H; Bartos MC; Krupa P; Vitovcova B; Pleskacova Z; Kasparova P; Dvorakova K; Skarkova V; Petera J
Diagnostics (Basel); 2023 Jul; 13(15):. PubMed ID: 37568909
[TBL] [Abstract][Full Text] [Related]
2. Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival.
Korkolopoulou P; Levidou G; El-Habr EA; Adamopoulos C; Fragkou P; Boviatsis E; Themistocleous MS; Petraki K; Vrettakos G; Sakalidou M; Samaras V; Zisakis A; Saetta A; Chatziandreou I; Patsouris E; Piperi C
Br J Cancer; 2013 May; 108(10):2142-52. PubMed ID: 23619925
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MEOX2 in gliomas.
Tachon G; Masliantsev K; Rivet P; Petropoulos C; Godet J; Milin S; Wager M; Guichet PO; Karayan-Tapon L
Mod Pathol; 2019 Jun; 32(6):774-786. PubMed ID: 30659268
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
5. SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.
Yu L; Dong Y; Xue J; Xu S; Wang G; Kuang D; Duan Y
Diagn Pathol; 2022 Jan; 17(1):2. PubMed ID: 34996493
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Joseph NM; Phillips J; Dahiya S; M Felicella M; Tihan T; Brat DJ; Perry A
Mod Pathol; 2013 Mar; 26(3):315-26. PubMed ID: 23041832
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
8. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
[TBL] [Abstract][Full Text] [Related]
9. EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.
Burel-Vandenbos F; Benchetrit M; Miquel C; Fontaine D; Auvergne R; Lebrun-Frenay C; Cardot-Leccia N; Michiels JF; Paquis-Flucklinger V; Virolle T
J Neurooncol; 2011 Apr; 102(2):171-8. PubMed ID: 20652725
[TBL] [Abstract][Full Text] [Related]
10. Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.
Karlowee V; Amatya VJ; Hirano H; Takayasu T; Nosaka R; Kolakshyapati M; Yoshihiro M; Takeshima Y; Sugiyama K; Arita K; Kurisu K; Yamasaki F
Pathobiology; 2017; 84(2):99-107. PubMed ID: 27553586
[TBL] [Abstract][Full Text] [Related]
11. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Takano S; Tian W; Matsuda M; Yamamoto T; Ishikawa E; Kaneko MK; Yamazaki K; Kato Y; Matsumura A
Brain Tumor Pathol; 2011 Apr; 28(2):115-23. PubMed ID: 21344322
[TBL] [Abstract][Full Text] [Related]
12. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
[TBL] [Abstract][Full Text] [Related]
13. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an IDH1 R132H Rabbit Monoclonal Antibody, MRQ-67, and Its Applications in the Identification of Diffuse Gliomas.
Copaciu R; Rashidian J; Lloyd J; Yahyabeik A; McClure J; Cummings K; Su Q
Antibodies (Basel); 2023 Feb; 12(1):. PubMed ID: 36810519
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Fraser AR; Bacci B; le Chevoir MA; Long SN
J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
[TBL] [Abstract][Full Text] [Related]
16. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
[TBL] [Abstract][Full Text] [Related]
17. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of HIF-1α, IDH1 and TP53: Prognostic profile of Moroccan patients with diffuse glioma.
Sfifou F; Ouzir M; Hakkou EM; Obtel M; Errihani H; Bouzidi AA; Abouqal R; El Ouahabi A; Cherradi N
J Chem Neuroanat; 2022 Jan; 119():102056. PubMed ID: 34871733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
